Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Janux Therapeutics Inc.

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Janux Therapeutics Inc on November 7 and set a price target of $58.00....

Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

Janux Therapeutics, Inc. (($JANX)) announced an update on their ongoing clinical study. Janux Therapeutics, Inc. is conducting a Phase 1 study titl...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JANX	$28.80	+0.73%	796.07K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JANX	$28.80	+0.7%	796.07K
3
4
5
6

JANX

JANX

Get Janux Therapeutics Inc. Data in Excel

Get Janux Therapeutics Inc. Data in Excel